Clinical Research Directory

Inclusion Criteria: * In order to be eligible to participate in this study, a subject must meet all of the following criteria: * Age ≥ 18 years * Able to understand the written information and able to give informed consent * Melanoma diagnosis with planned ICI treatment according to standard of care (nivolumab, pembrolizumab, monotherapy or combination therapy with ipilimumab) * Presence of atherosclerosis in the descending thoracic aorta at baseline. Exclusion Criteria: * Pregnancy or lactation * Baseline statin use or previously reported statin intolerance * Current or recent (≤1 year) history of alcohol or drug abuse * Contra-indication for statin therapy, including: * Active liver disease, including ALT/AST levels ≥ 3x ULN * (History of) myopathy Congenital muscular disorder History of (drug-induced) rhabdomyolysis History of drug-induced myopathy with elevated creatine kinase (CK) * Severe kidney failure (creatinine clearance \< 30 ml/min) * Use of essential medication with (potential) interactions with atorvastatin, including: * strong CYP3A4 inhibitors such as clarithromycin, ciclosporin, itraconazol, ketoconazole, voriconazol, posconazol, HCV agents, HIV protease inhibitors * BCRP inhibitors such as elbasvir and grazoprevir * Fibrates (including gemfibrozil) * Life expectancy \< 12 months * High MESA-score at baseline